| Abstrakt: |
A recent study conducted by researchers at Southern Medical University in Guangzhou, China, explored the use of flumatinib as a first-line therapy for patients with newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML). The study enrolled 127 patients and found that flumatinib was not inferior to other tyrosine kinase inhibitors (TKIs) such as nilotinib and dasatinib. The primary endpoint of the study was early molecular response rates at 3 months, and the secondary endpoints included rates of complete cytogenic response and major molecular response at various time points. The study concluded that flumatinib was well-tolerated and showed promising results in treating CP-CML. [Extracted from the article] |
